Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA Database

Eric Milan Mukherjee MD PhD[1, 2], Dodie Park[2], Matthew S. Krantz MD[2,3], Cosby A. Stone Jr. MD MPH[2,3], Michelle Martin-Pozo PhD[2,3], Elizabeth Phillips MD[2,3,4*]

[1]Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

[2]Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

[3]Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA

[4]Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia

*Corresponding author: elizabeth.j.phillips@vumc.org

Keywords: Severe Cutaneous Adverse Reactions, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction with Eosinophilia and Systemic Symptoms, Acute Generalized Exanthematous Pustulosis, Pharmacovigilance, FAERS.

World Count: 3000

Abstract

Importance: Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS-TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed drug eruption (GBFDE), are rare but life-threatening drug hypersensitivity syndromes. Due to their low incidence and diagnostic complexity, large-scale characterization of SCAR is challenging.

Objective: To characterize the demographics, causative agents, trends, latency, and phenotypic overlap of SCAR using a large-scale, sanitized pharmacovigilance dataset from FAERS (FDA Adverse Event Reporting System).

Design: Cross-sectional study of spontaneous adverse event reports. Cases were drawn from the U.S. Food and Drug Administration Adverse Event Reporting System (FDA FAERS) from January 2004 to December 2023 and subjected to sanitization and deduplication. Disproportionality analysis was used to characterize causative agents. Machine learning (random forest classifiers) was used to analyze predictors of drug latency and mortality.

Setting: Global pharmacovigilance reports submitted to FAERS.

Participants: A total of 56,683 deduplicated SCAR reports were identified, representing 0.33% of reports during the study period.

Exposures: Suspected causative drugs, including both small molecules and biologics.

Main Outcomes and Measures: Main outcomes included the frequency and distribution of SCAR syndromes, reporting trends over time, latency from drug start to reaction onset, drug-specific disproportionality (PRR, ROR, IC), and co-reporting between SCAR types and related conditions.

Results: A total of 56,683 unique SCAR reports were identified, including SJS-TEN (28,871), DRESS (22,444), AGEP (6,183), and GBFDE (150). We identified 237 drugs with significant disproportionality for SCAR overall. Co-reporting between SCARs was significantly enriched ($p < 1e–200$), suggesting overlapping phenotypes. Latency varied by drug and syndrome (median: GBFDE 3 days, AGEP 4 days, SJS-TEN 12 days, DRESS 20 days).

Conclusions and Relevance: SCAR syndromes display distinct but overlapping phenotypes, with variable latency and diverse causative agents. These findings, based on the largest SCAR dataset to date, highlight the need for improved classification frameworks and molecular validation. Large-scale pharmacovigilance, integrated with genomic and histopathologic data, will be critical to improving diagnosis, mechanistic understanding, and clinical management of SCAR.

Introduction

Adverse drug reactions (ADR) are one of the top 10 causes of death in the developed world, costing up to $130 billion annually in the US.[1] Among the most serious ADRs are severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS-TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and generalized bullous fixed drug eruption (GBFDE). These conditions are distinguished by morphology, causative agents, systemic involvement, and latency. For instance, AGEP and GBFDE manifests within days of exposure, while DRESS and SJS-TEN can take weeks.[2]

SCAR has incidence of 0.4 to 0.6 per million/year in the developed world, with mortality up to 70 percent in high-risk populations.[2] SCAR can lead to signficant skin damage, systemic involvement, and long-term sequelae. Because of their rarity, SCAR are difficult to study at scale. The largest published retrospective studies of SCAR have 300-400 cases, while the largest meta-analysis of SJS-TEN had 2917 patients.[3,4] Given it's rarity, there are many unanswered questions, including intermediate phenotypes between different SCAR, variations in mortality and phenotype between causative agents, and geographic and temporal variation.

The FDA Adverse Event Reporting System (FAERS) is a valuable public database collecting information on ADRs. FAERS contains millions of reports submitted by providers, patients, and manufacturers. However, FAERS is hampered by unstructured drug names, duplication, and inconsistent detail.[5] Understanding phenotype-specific latency distributions can guide discontinuation decisions in hospitalized patients. Likewise, knowledge of drug disproportionality profiles – both high-risk and unexpectedly low-risk agents – can refine differential diagnosis and influence prescribing practices in dermatology, oncology, infectious diseases, and primary care.

In this study, we sanitized FAERS and analyzed reports from 2004 to 2023, focusing on temporal trends, disproportionality, and overlap conditions. By pairing rigorous data cleaning with clinically oriented analyses, our goal was to generate findings that can be directly applied to patient care, supporting earlier recognition, more accurate classification, and more targeted management of these life-threatening reactions.

Methods

Coding was done in RStudio 2024.12.0 Build 467 with R version 4.4.2, PyCharm 2024.2.0.1 with Python 3.12, PostgreSQL 16.3 (with PgAdmin IV), with GPT4o assistance. Details are available in the **Online Supplement**.

Data

Quarterly ASCII files were fed into AEOLUS, which maps drugs and outcomes to standardized vocabularies and deduplicates by removing cases that match all four demographic fields (event date, age, sex and reporter country) using the previously published AEOLUS model.[6] Unmapped drugs and outcomes were manually mapped by two researchers (EMM and DP), resulting in 100% mapping of rows in both tables. After filtering and outlier removal, 13633 SCAR cases had sufficient data for TTE analysis.

Disproportionality Analysis

To evaluate drug-event associations, we constructed 2×2 contingency tables for each drug–SCAR pair using unique patient identifiers. Patients exposed to a given drug (as primary suspect) and those with a reported SCAR event were identified, and the intersection defined the count of cases (cell a). The remaining cells (b, c, and d) were derived based on the total number of unique patients across drug and event datasets. Disproportionality metrics – including the proportional reporting ratio (PRR), reporting odds ratio (ROR), and Information Component (IC) based on Bayesian Confidence Propagation Neural Networks – were calculated with 95% confidence intervals, with formulas detailed in the online supplement. Chi-squared values with Yates' correction were calculated using base R. We identified significant associations by evaluating whether the lower bound of the 95% confidence interval exceeded 1 for PRR and ROR, or 0 for IC (IC025).

Overlap Analysis

For overlap analyses, a patient was considered to have an overlap phenotype if their outcome data had at least one term from each of two different SCAR. For overlaps between cutaneous ADR, p-values were calculated using the binomial test (assuming a random draw from the entire FAERS database), with Benjamini-Hochberg correction for multiple testing.

Results

Demographics

After deduplication and data cleaning, a total of 56,683 SCAR cases were identified, representing 0.33% of all unique patient reports in FAERS from January 2004 to December 2023 (**eFigure 1**). This process began with

over 20.8 million unique patient identifiers (PIDs) linked across the FAERS Reaction, Drug, Outcome, Demographics, and Therapeutics files. Drug and adverse event terms were mapped to standardized vocabularies using the AEOLUS method, followed by manual mapping of any unmapped entries (1.4% of drug rows and <0.01% of adverse event rows). Only fully mapped, deduplicated records were retained for downstream analyses, yielding 17.2 million unique PIDs with sanitized drug-outcome pairs.

Among these, the most frequently reported phenotype was SJS-TEN (28,871 cases), followed by DRESS (22,444), AGEP (6,183), and GBFDE (150). Temporal trends showed a steady increase in SCAR reporting over the study period, peaking in 2019. While SJS-TEN counts have remained relatively stable, DRESS reports have risen consistently, surpassing SJS-TEN as the most frequently reported SCAR annually since 2017.

Age statistically differs between SCAR, with GBFDE having lowest median (46 years, IQR [35-65]), then SJS-TEN (52 years, [30-68]), DRESS (52 years, [31-66]), and AGEP (59 years, [41-73]). Each SCAR shows female predominance except GBFDE. Analyzing sex and age (**eFigure 2**) shows that males have a bimodal age distribution, while female patients overtake males in adolescence before "catching up" in older age. Reports originate from 140 countries and territories (**eFigure 3 and 4**). USA (15607), France (9530), and Japan (5248) contributed the most reports. SJS-TEN outnumbers DRESS in all top 10 countries except for France, Spain, and Portugal, possibly due to trends in reporting and prescription. India reports the most GBFDE (44 cases), followed by France (28), the US (15) and Iran (15).

Temporal Trends in Causative Agents

Using criteria from Evans et al (>2 cases, PRR ≥ 2, chi-squared ≥ 4), we find 237 drugs with positive signal when aggregating all SCAR together (**Supplemental Table**).[7] When splitting by phenotype, there were 229 drugs with a positive signal for SJS-TEN, 161 for DRESS, 130 for AGEP, and 16 for GBFDE.

We analyzed temporal trends in SCAR reporting (**Figure 2**). The top five causative agents (allopurinol, vancomycin, lamotrigine, ibuprofen, and carbamazepine) are consistently responsible for ~20% of new reports. The proportion of new reports due to biologics has steadily increased over time ($p < 0.0001$ by the Cochrane-Armitage test), comprising 8.2% of new reports in 2023, up from 2.6% in 2015 and 1.2% in 2004. Subdividing biologics by function, cases associated with immune checkpoint inhibitors (ICIs) have increased steadily since their 2011

approval ($p < 0.0001$, Cochrane-Armitage), comprising 49.1% of reports with a biologic as the primary suspect in 2023.

Disproportionality Analysis

Figure 3 plots the information content (IC) of the top ≤20 drugs with >2 cases. **eFigure 4** shows the top 100 drugs when aggregating all SCAR together. Several well-known culprits (e.g. lamotrigine, allopurinol, and phenytoin for SJS-TEN, allopurinol, vancomycin, and lamotrigine for DRESS) are strongly associated (IC ≥ 3). Other, less-well-known associations (e.g., enfortumab and zonisamide for SJS-TEN, ciprofloxacin and valacyclovir for DRESS) have clear positive signals.[8–10]

Interestingly, some suspects have negative IC (**eFigure 5**), meaning they are less frequently associated with SCAR than expected. Many of these (lenalidomide, adalimumab, etanercept, and ocrelizumab) are immunomodulators infrequently (and controversially) implicated in individual cases.[11–13] Their negative signal in a large-scale pharmacovigilance analysis may reflect several factors: a true lower propensity to cause T cell-mediated cytotoxic injury, competing risks from alternative cutaneous toxicities that dominate their safety profile, or indication bias, where their target populations are monitored closely and alternate etiologies are more readily identified. Similarly, some hormonal medications (testosterone, levonorgestrel), psychiatric medications (methylphenidate, aripiprazole), and anti-osteoporotic agents (denosumab, zoledronic acid) also demonstrated negative IC values. For these drugs, the negative disproportionality may indicate that their sporadic associations with SCAR in the literature are coincidental, related to comedication effects, or represent misattribution in the context of complex polypharmacy.

Disproportionate Co-Reporting

Overlap conditions between SCAR are rare, difficult to diagnose, and controversial in the literature.[14] Disproportionality of co-occurring SCAR is shown in **Figure 4**. For SJS-TEN/DRESS, allopurinol (71 cases), lamotrigine (71), and phenytoin (49) are the most frequent suspects and have IC > 3. Co-reporting with AGEP is rarer; phenytoin (26 cases), ciprofloxacin (18), and allopurinol (14) are the most frequent culprits with co-reported DRESS, all with IC > 3, and phenytoin (34 cases), amlodipine (29), and ibuprofen (13) are the most frequent suspects of co-reported SJS-TEN.

To better understand co-reporting patterns and to account for the possibility of misdiagnosis, we analyzed cases reporting more than one SCAR phenotype and examined co-reporting with other generalized cutaneous adverse drug reactions (ADR) that may mimic SCAR in clinical presentation. These included autoimmune blistering disorders such as pemphigus and pemphigoid, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), fixed drug eruption (FDE), linear IgA bullous dermatosis (LABD), and systemic contact dermatitis (**eFigure 7**). Strong statistical enrichment was seen for overlap between SCAR phenotypes, including 231 cases of SJS-TEN/AGEP ($p = 2.37 \times 10^{-206}$), 576 cases of SJS-TEN/DRESS ($p < 1 \times 10^{-207}$), and 205 cases of AGEP/DRESS ($p = 3.5 \times 10^{-194}$). These findings suggest that certain drug-induced eruptions either present with overlapping clinical and histopathologic features or are prone to diagnostic ambiguity in spontaneous reporting.

Co-reporting between SCAR and non-SCAR cutaneous ADR was less common but still notable in specific pairings. The strongest associations occurred between SJS-TEN and LABD (43 cases, $p = 9.65 \times 10^{-41}$) and between SJS-TEN and pemphigoid (63 cases, $p = 1.45 \times 10^{-28}$). Co-reporting was also enriched between pemphigoid and LABD (14 cases, $p = 1.29 \times 10^{-15}$) and between pemphigus and pemphigoid (44 cases, $p = 2.18 \times 10^{-35}$), consistent with known clinical and histologic overlap between these autoimmune blistering diseases. These patterns highlight the limitations of spontaneous reporting for phenotypes that require histopathologic confirmation, and underscore the need for harmonized definitions and integration of pathology.

Latency Varies by Causative Drug and SCAR

We conducted TTE analysis on a subset of cases (n = 13,633, **Figure 5A**). Latency differed by phenotype ($p < 0.0001$ by log-rank), with GBFDE having the shortest (3 days, IQR [2-3], n = 5), followed by AGEP (4d, [2-9], n = 1541), SJS-TEN (12d, [6-23], n = 7230), and DRESS (20d, [9-31], n = 5021). Median latency varies substantially by causative drug (**Figure 4B**). For SJS-TEN, NSAIDs (ibuprofen, acetaminophen) and antibiotics (ceftriaxone, amoxicillin, azithromycin) have short latency, while ICI (pembrolizumab, nivolumab), allopurinol, and some anticonvulsants (zonisamide and phenytoin) have long latency. For DRESS, ibuprofen, amoxicillin, and the kinase inhibitor vemurafenib have short latencies, while the protease inhibitor telaprevir has a median latency of 42 days. For AGEP, a few drugs have long latency (vancomycin, hydroxychloroquine, terbinafine).

Discussion

We report a comprehensive cross-sectional analysis of 56,683 SCAR cases from FAERS, 10-100x more than previous studies. SCAR reporting in FAERS has increased over time. For DRESS, this is likely due to the condition first being named in 1996, criteria being published in the mid-2000s, and FAERS first reporting in 2003.[15] GBFDE, known since the 1980s, has only been reported in FAERS since 2021.[16] While the plurality of reports are from high-resource nations, there are many reports from middle- and lower-income nations, reflecting SCAR's global nature and the need for further global reporting.

Reported causative agents include well-known culprits like beta-lactams, anticonvulsants, and allopurinol, and less-studied agents like immunomodulators. The FDA's Drug Safety-related Labeling Changes (SrLC) lists nine drugs since 2016 with label changes due to a link with SJS-TEN and/or DRESS – lamotrigine, allopurinol, phenytoin, carbamazepine, amoxicillin, trimethoprim-sulfamethoxazole (TMP-SMX), rifampin, levetiracetam, and vancomycin.[17] Importantly, four of these drugs with the most label changes since 2016 for SCAR, DRESS, and/or SJS-TEN (allopurinol – 4 changes, phenytoin – 6 changes, rifampin – 5 changes, and TMP-SMX – 4 changes), are the same drugs that we found to be disproportionately represented in our data, providing evidence of the robustness of our methods but also indicating that these label changes may have impacted reporting.

The impact of these findings is underscored by the methods used to prepare FAERS, and by the breadth of medications studied. Prior studies have been limited by smaller sample sizes or focus on a few drugs.[18,19] Additionally, prior studies have not been as thorough in sanitization, including limited deduplication efforts and lack of stringency in drug naming. The issue of deduplication is well-documented in the literature, and is an area of active improvement.[5,20]

Even with our efforts, clear limitations remain. Because FAERS relies on voluntary and spontaneous reporting and lacks stringent diagnostic requirements for any given condition (e.g., DRESS or AGEP cases do not require confirmation by RegiSCAR or EuroSCAR criteria), it cannot be used to estimate incidence or prevalence, may lead to reporting biases, and remains susceptible to misdiagnosis. One source of error arises from confusion between phenotypically similar but etiologically distinct diseases, such as TEN-like pemphigoid, in which autoimmune blistering disorders mimic the widespread epidermal necrosis and mucosal involvement of SJS-TEN.[21] Additional challenges include variable detail across reports – some omit concomitant drug data, exact dates, or full phenotyping – and the persistence of residual duplicate entries and typographical errors despite systematic cleaning. More advanced methods based on natural language processing and probabilistic grouping could further address

these issues in future studies, alongside harmonized diagnostic criteria and the creation of specific MedDRA terms for emerging phenotypes.[22]

Emerging Agents, Overlap Conditions and Mimickers

Particularly striking is the rise of ICI-induced SCAR, which presents a mechanistic challenge: whereas small molecules are thought to cause SCAR through direct perturbation of the T-cell receptor/peptide/MHC interface, ICIs may trigger reactions by releasing peripheral tolerance, resulting in a broad spectrum of immune-related adverse events, including SJS-TEN-like presentations.[23] ICIs in our dataset were associated with longer latencies compared to traditional culprits, suggesting a distinct pathophysiology. It remains unclear whether these reactions represent true SJS-TEN or a distinct phenotype like PIRME.[24] Additionally, ICIs may lower the threshold for small-molecule-induced SCAR, suggesting that some cases may be mis-attributed.[25,26]

A similar ambiguity is the antibody-drug conjugate enfortumab vedotin, which has been reported to cause both “classic” SJS-TEN and an SJS-TEN-like eruption histologically similar to toxic erythema of chemotherapy, likely due to direct toxicity on keratinocytes.[27] Together, these findings suggest that immunotherapy-related mucocutaneous toxicity may span a spectrum that intersects, but is not identical to, classic SCAR.

Full phenotyping and histopathology are often required to diagnose conditions meeting the criteria of >1 SCAR. While such data is unavailable in FAERS, our work offers some insights. We demonstrate that co-reporting is higher than expected by random assortment and occurs more frequently than with other cutaneous conditions commonly misdiagnosed for each other (e.g. autoimmune bullous disease). This co-reporting may reflect either misdiagnosis, clinical ambiguity, or a true overlapping phenotype.

SJS-TEN/DRESS overlap, meaning cases meeting criteria for both diseases, has been reported with allopurinol, anticonvulsants and TMP-SMX, among others.[28,29] AGEP/DRESS overlap is more difficult – the condition is recognized as a discrete entity within FAERS; in our data it appears in one case (primary suspect levofloxacin). Pustular DRESS is a known phenotype, with vancomycin, phenytoin, doxycycline and piperacillin-tazobactam implicated in a recent review (noting that these patients didn’t meet full AGEP criteria).[30] A retrospective study of 216 patients found one probable case of DRESS-AGEP overlap meeting both criteria.[31] Similarly, AGEP with TEN-like features, or AGEP/SJS-TEN overlap, is increasingly recognized.[32] Many present with widespread desquamation and mucosal involvement that appears SJS-TEN-like, but with pathology showing pustules. Because

histopathology is needed, many cases of both true AGEP/SJS-TEN overlap and AGEP with SJS-TEN-like features are likely misdiagnosed. Further harmonization of criteria and coordination are needed to characterize these cases.

Causative Agents and Latency

Drug latency is critical in the management of SCAR, as different SCAR phenotypes differ significantly by latency, as reproduced in our data. In tandem with drug timelines, prior knowledge of latency is vital to determining the causative agent in complex cases. We have demonstrated that causative agents have a strong influence on latency, and that some agents have unusually long or short latencies, which is valuable knowledge in a clinical setting.

A few causative agents stand out in terms of unusually long or short latencies. The long latency of hydroxychloroquine-induced and terbinafine-induced AGEP has been described, in stark contrast to AGEP's usual very short latency.[33,34] SJS-TEN attributed to pembrolizumab and nivolumab also has a longer latency, consistent with the literature on PIRME.[24] Vemurafenib has previously been attributed to rapid-onset DRESS.[35] The reason for the dependence of latency on causative agent is not well-understood and bears further study, perhaps by considering chemical structure, metabolism, and time needed for antigen presentation.

A controversy in the field of SCAR is protopathic bias – namely, when a drug is misattributed as causative because it is prescribed early during SCAR to another drug. This is particularly notable for NSAIDs, which are often prescribed in the flu-like prodromal phase of SJS-TEN, and which have low latency (4-5 days) in our data. An internal FDA review suggested acetaminophen caused rash, and mucosal erosion with a 1-3 day delay.[36] Some antibiotics like amoxicillin and azithromycin may be protopathic due to being prescribed for subjective malaise during the prodromal phase of SCAR, and both demonstrate shorter latency in our data. A concerted effort to confirm these cases with follow-up testing would be helpful.

Conclusion and Future Directions

SCAR remains among the most devastating complications of pharmacotherapy, yet their rarity and complexity make them challenging to study in traditional clinical cohorts. Large-scale pharmacovigilance databases offer a unique opportunity to investigate SCAR at population scale, aggregating global data to identify trends, signals, and emerging culprits. In this study, we applied refined deduplication strategies and multi-dimensional analyses to characterize the epidemiology, latency, and phenotypic overlap of SCARs across more than 56,000 reports.

In parallel, the growing complexity of SCAR phenotypes demands new frameworks for classification that go beyond current syndrome labels. Emerging entities like PIRME, pustular DRESS, and AGEP with SJS-TEN-like features illustrate how existing diagnostic categories may fail to capture heterogeneity. Future efforts should prioritize harmonization of diagnostic criteria across SCAR, standardized integration of electronic health record information and histopathologic data, and adoption of probabilistic or spectrum-based models of classification. This will be essential not only for pharmacovigilance, but also for improving the design of trials, mechanistic studies, and treatment algorithms for these rare but life-threatening reactions.

Data Sharing

Methods and data are available at https://github.com/capuhcheeno/SCARs_ICI-Manuscript-Scripts.

Contributions

EMM conceived the project, wrote the manuscript, and conducted all analyses. DP conducted analysis and edited the manuscript. MMP, MSK, and CAS assisted with analysis and reviewed the manuscript. EP reviewed all analyses and the manuscript.

Acknowledgements

E.J.P. is supported by the following grants from the National Institutes of Health (NIH): NIH U01AI154659, NIH P50GM115305, NIH R01HG010863, NIH R21AI139021, NIH R01AI152183, and NIH 2 D43 TW010559. E.J.P. is also supported by the National Health and Medical Research Council of Australia. E.M.M. is funded by a Vanderbilt University Medical Center internal career development award (Vanderbilt Faculty Research Scholars).

Conflict of Interest

E.J.P. receives royalties and consulting fees from UpToDate and UpToDate Lexidrug (where she is a Drug Allergy Section Editor and section author) and has received consulting fees from Janssen, Vertex, Verve, Servier, Rapt and Esperion. E.J.P. is co-director of IIID Pty Ltd, which holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity, and E.J.P has a patent pending for detection of HLA-A*32:01 in connection with diagnosing drug

reaction with eosinophilia and systemic symptoms to vancomycin. For these patents she does not receive any financial remuneration, and neither are related to the submitted work.

Statement on Use of Artificial Intelligence

GPT4o was used to write, optimize, and debug R, SQL and Python code and improve language. Suggestions were cross-referenced in literature, package documentation, and resources like stackoverflow.com. All code and generated data were manually reviewed, tested, and verified by the authors. The authors take responsibility for all code generated and for all text.

References

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*. 1998;279(15):1200-1205. doi:10.1001/jama.279.15.1200

2. Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions. *Nat Rev Dis Primers*. 2024;10(1):30. doi:10.1038/s41572-024-00514-0

3. Creadore A, Desai S, Alloo A, et al. Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. *JAMA Dermatology*. 2022;158(2):176-183. doi:10.1001/jamadermatol.2021.5390

4. Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. *J Invest Dermatol*. 2018;138(11):2315-2321. doi:10.1016/j.jid.2018.04.027

5. Giunchi V, Fusaroli M, Hauben M, Raschi E, Poluzzi E. Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach. *Drug Saf*. 2023;46(10):921-926. doi:10.1007/s40264-023-01345-w

6. Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. *Sci Data*. 2016;3:160026. doi:10.1038/sdata.2016.26

7. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf*. 2001;10(6):483-486. doi:10.1002/pds.677

8. Nguyen MN, Reyes M, Jones SC. Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. *JAMA Dermatology*. 2021;157(10):1237-1239. doi:10.1001/jamadermatol.2021.3450

9. Vivar KL, Mancl K, Seminario Vidal L. Stevens–Johnson syndrome/toxic epidermal necrolysis associated with zonisamide. *Clin Case Rep*. 2017;6(2):258-261. doi:10.1002/ccr3.1288

10. Alkhateeb H, Said S, Cooper CJ, Gaur S, Porres-Aguilar M. DRESS syndrome following ciprofloxacin exposure: An unusual association. *Am J Case Rep*. 2013;14:526-528. doi:10.12659/AJCR.889703

11. Allegra A, Alonci A, Penna G, et al. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. *Hematol Oncol*. 2012;30(1):41-45. doi:10.1002/hon.1000

12. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. *World J Gastroenterol*. 2009;15(35):4449-4452. doi:10.3748/wjg.15.4449

13. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. *Ann Oncol*. 2002;13(12):1948-1950. doi:10.1093/annonc/mdf350

14. Horcajada-Reales C, Pulido-Pérez A, Suárez-Fernández R. Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist? *Actas Dermo-Sifiliográficas (English Edition)*. 2016;107(1):23-33. doi:10.1016/j.adengl.2015.11.003

15. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. *Br J Dermatol*. 2007;156(5):1083-1084. doi:10.1111/j.1365-2133.2007.07807.x

16. Kauppinen K, Stubb S. Fixed eruptions: causative drugs and challenge tests. *Br J Dermatol*. 1985;112(5):575-578. doi:10.1111/j.1365-2133.1985.tb15266.x

17. Drug Safety-related Labeling Changes (SrLC). Accessed February 26, 2025. https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/

18. Zhou L, Yang J, Xiao M, et al. Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events. *Expert Opinion on Drug Safety*. 0(0):1-8. doi:10.1080/14740338.2023.2278685

19. Mao K, Li J, Zhu X, Sun H, Zhong S, Mao W. Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database. *Expert Rev Clin Pharmacol*. 2024;17(1):101-110. doi:10.1080/17512433.2023.2294002

20. Kiguba R, Isabirye G, Mayengo J, et al. Navigating duplication in pharmacovigilance databases: a scoping review. *BMJ Open*. 2024;14(4):e081990. doi:10.1136/bmjopen-2023-081990

21. Nikyar Z, Hatami P, Aryanian Z, Sotoudeh S, Ziaee V, Goodarzi A. An Unusual TEN-Like Presentation of Juvenile Bullous Pemphigoid: A Diagnostic Challenge. *Case Rep Dermatol Med*. 2022;2022:8507156. doi:10.1155/2022/8507156

22. Kreimeyer K, Spiker J, Dang O, De S, Ball R, Botsis T. Deduplicating the FDA adverse event reporting system with a novel application of network-based grouping. *J Biomed Inform*. 2025;165:104824. doi:10.1016/j.jbi.2025.104824

23. Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. *J Am Acad Dermatol*. 2020;83(5):1475-1477. doi:10.1016/j.jaad.2020.03.029

24. Sangani KA, Lee V, Schroedl L, Shea CR, Onajin O, Chadha AA. Progressive Immunotherapy-Related Mucocutaneous Eruption: A Mimicker of SJS-TEN. *Am J Dermatopathol*. Published online July 30, 2025. doi:10.1097/DAD.0000000000003083

25. Grice S, Saide K, Farrell L, et al. Immune checkpoint blockade lowers the threshold of naïve T-cell priming to drug-associated antigens in a dose-dependent fashion. *Toxicol Sci*. 2024;202(1):13-18. doi:10.1093/toxsci/kfae118

26. Hammond S, Olsson-Brown A, Grice S, et al. Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. *Toxicological Sciences*. 2022;186(1):58-69. doi:10.1093/toxsci/kfab144

27. Khanjar B, Sejdiu Z, Mitre M, Mancebo S, Magro C, Harp J. Enfortumab vedotin toxic epidermal necrolysis–like blistering dermatosis: A case series and review of the literature. *JAAD Case Reports*. 2024;43:40-50. doi:10.1016/j.jdcr.2023.10.025

28. Van Nguyen K, Van Vu Q, Tran MH, et al. Overlapping Stevens-Johnson Syndrome and DRESS Syndrome Caused by Phenobarbital: A Vietnamese Case Report. *Glob Pediatr Health*. 2023;10:2333794X231216556. doi:10.1177/2333794X231216556

29. Chin LD, MacGillivary ML, Purdy KS, Kirshen C. Stevens-Johnson syndrome with overlapping features of DRESS syndrome: A report of two cases. *SAGE Open Medical Case Reports*. 2024;12:2050313X241307097. doi:10.1177/2050313X241307097

30. Hansen E, Kirven RM, Gallardo M, et al. Drug Reaction With Eosinophilia and Systemic Symptoms With Pustulosis. *JAMA Dermatology*. 2024;160(7):777-779. doi:10.1001/jamadermatol.2024.1082

31. Bouvresse S, Valeyrie-Allanore L, Ortonne N, et al. Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist? *Orphanet Journal of Rare Diseases*. 2012;7(1):72. doi:10.1186/1750-1172-7-72

32. Chowdhury TA, Talib KA, Patricia J, Nye KD, Moosa SA. Rare and Complicated Overlap of Stevens-Johnson Syndrome and Acute Generalized Exanthematous Pustulosis. *Cureus*. 2021;13(6):e15921. doi:10.7759/cureus.15921

33. Chaabouni R, Bahloul E, Ennouri M, et al. Hydroxychloroquine-induced acute generalized exanthematous pustulosis: a series of seven patients and review of the literature. *Int J Dermatol*. 2021;60(6):742-748. doi:10.1111/ijd.15419

34. de Oliveira GV, Maia MLP, Leão FAA, et al. What to expect when AGEP is induced by terbinafine? Case report and critical review of the literature. *Mycoses*. 2022;65(10):918-925. doi:10.1111/myc.13506

35. Munch M, Peuvrel L, Brocard A, et al. Early-Onset Vemurafenib-Induced DRESS Syndrome. *Dermatology*. 2015;232(1):126-128. doi:10.1159/000439272

36. Amending Over-the-Counter Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use | FDA. Accessed February 8, 2025. https://dps.fda.gov/omuf/ordersearch/order_otc000035

Figure Legends

Figure 1. Demographic Summary of SCAR. (A) SCAR reporting over time in FAERS, by quarter. (B) Age distribution by SCAR. Pairwise comparisons done by Wilcoxon signed-rank test. **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$. (C) Sex Distribution by SCAR. All patients without "M" or "F" sex markers were classified as "other". (D) Top 10 Countries by SCAR cases. US - United States, FR - France, JP - Japan, GB - Great Britain, ES - Spain, IT - Italy, DE - Germany, CA - Canada, IN - India, PT - Portugal.

Figure 2. Trends in SCAR Reporting. Number of reports were aggregated by approximately-equal-frequency bins. (A) Number of SCAR reports whose primary cause is a "top 5" small molecule (allopurinol, carbamazepine, ibuprofen, lamotrigine, vancomycin), another small molecule, or a biologic. (B) Number of SCAR reports subdivided by type of biologic. ICI = immune checkpoint inhibitor. (C) Proportion of SCAR reports by drug category over time. Proportion of biologics has increased over time ($p < 0.0001$ by Cochrane-Armitage test). (D) Proportion of total biologic-related SCAR reports subdivided by type. Proportion of ICI has increased over time ($p < 0.0001$ by Cochrane-Armitage test).

Figure 3. Disproportionality Analysis. Top <20 drugs for each SCAR by number of cases (with a minimum of 3 cases) are displayed. Each point represents the IC of a given drug-SCAR combination, with the total number of cases noted just above. Confidence intervals span IC025 to IC975. Red dashed line represents IC of 3, suggesting strong disproportionality.

Figure 4. Disproportionality Analysis and Co-reporting of SCAR. Information component, with 95% confidence interval (IC025 to IC975) is plotted for all medications with at least 3 cases of co-reported SCAR. Inset: number of patients with co-reported SCAR, pairwise. Elements on the diagonal are the total patients with each SCAR.

Figure 5. Drug Latency. (A) Survival curves show clear variation in median TTE/latency per SCAR. P-value by log-rank test. (B) Drug latency varies by causative drug, within each SCAR. The top 40 drugs (by number of cases) were plotted for each SCAR (GBFDE was excluded due to low number of cases). Each point represents median latency for that drug-SCAR combination, with IQR around the median. The "All Drugs" row for each SCAR shows the mean latency for each SCAR for all drugs (including those not displayed).

eFigure Legends

eFigure 1. FAERS Deduplication and Sanitization. Quarterly FAERS data files are deduplicated and combined, with drugs and outcomes mapped to standard terms. Any unmapped drugs and outcomes were manually mapped to standardized terms. From a data set of n = 17201564 unique patient IDs (PIDs), 56683 have at least one reported SCAR. Of those cases, 13633 (24.1%) had sufficient data for TTE analysis.

eFigure 2. Age Versus Sex. Age distribution, separated by sex, were determined for (A) total SCAR and (B) separated individual SCAR.

eFigure 3. Geographic Distribution of SCAR. Number of reports of all SCAR are displayed.

eFigure 4. Geographic Distribution of Individual SCAR. Number of reports of individual SCAR are displayed

eFigure 5. Disproportionality Analysis of SCAR, Aggregated. Information component, along with 95% confidence interval (from IC025 to IC975) were calculated for the top 100 drugs by number of cases. Red dashed line at IC = 3 indicates strongly disproportionate associations.

eFigure 6. Drugs with the Most Negative Information Component (IC) for Each SCAR Phenotype. The drugs with the most negative IC values for SJS-TEN, DRESS and AGEP were plotted, indicating a weaker-than-expected association between these drugs and a given SCAR (compared to background rates). 95% confidence intervals (from IC025 to IC975) are plotted.

eFigure 7. Disproportionate Co-reporting Between Cutaneous Adverse Reactions. The number of patients with co-reported cutaneous adverse reactions are displayed on the off-diagonal elements, and elements on the diagonal are the total patients with each adverse reaction. P-values are calculated using the binomial test with Benjamini-Hochberg correction for multiple testing.


SCAR Cases By Year
Number of Cases
Year
AGEP
DRESS
GBFDE
SJS-TEN
Total SCAR


Age Distribution by SCAR Type
Age (years)
SCAR Type
AGEP
DRESS
GBFDE
SJS-TEN
Total SCAR
****
**
****


Sex Distribution by SCAR Type
Proportion
SCAR Type
AGEP
DRESS
GBFDE
SJS-TEN
Total SCAR
3362
10379
65
14651
28008
2211
9477
72
11064
22456
610
2588
13
3156
6219
F
M
Other


Top 10 Countries by SCAR Cases
Country
Number of Cases
US
FR
JP
GB
ES
IT
DE
CA
IN
PT
15607
9530
5248
2973
2033
1977
1623
1588
1166
1074
AGEP
DRESS
GBFDE
SJS-TEN


SCAR Reports Over Time: Biologics vs. Small Molecules
Number of Reports
Binned Years
[2004,2008)
[2008,2012)
[2012,2014)
[2014,2016)
[2016,2018)
2018
[2019,2021)
2021
2022
2023
69
138
85
122
209
148
418
277
309
348
4577
5522
3866
3880
3880
2868
6393
2733
2627
3002
822
1454
1193
1418
1741
1007
2070
906
852
890
Drug Classification
Biologic
Other Small Molecules
Top 5 Small Molecules


SCAR Reports Over Time by Biologic Type
Number of Reports
Binned Years
[2004,2013)
[2013,2017)
[2017,2019)
2019
2020
2021
2022
2023
37
32
20
27
30
52
46
86
2
44
119
92
83
124
138
171
157
118
96
54
75
70
98
69
36
41
21
13
17
14
16
11
12
20
16
9
18
17
11
11
Biologic Type
antineoplastic
ICI
immunomodulator
immunomodulator, antineoplastic
other


Proportion of SCAR Reports Over Time by Drug Category
% of Reports
Binned Years
[2004,2008)
[2008,2012)
[2012,2014)
[2014,2016)
[2016,2018)
2018
[2019,2021)
2021
2022
2023
Drug Category
Biologics
Other Small Molecules
Top 5 Small Molecules


Proportion of SCAR Reports Over Time by Biologic Type
% of Reports
Binned Years
[2004,2013)
[2013,2017)
[2017,2019)
2019
2020
2021
2022
2023
Biologic Type
antineoplastic
ICI
immunomodulator
immunomodulator, antineoplastic
other


Information Component (with 95% CI)
AGEP
clindamycin 223
amoxicillin 222
ibuprofen 217
vancomycin 210
terbinafine 153
hydroxychloroquine 146
ciprofloxacin 133
ceftriaxone 129
metronidazole 116
acetaminophen 107
levetiracetam 106
valacyclovir 94
acyclovir 93
diltiazem 93
azithromycin 87
omeprazole 87
levofloxacin 83
pantoprazole 82
esomeprazole 72
clavulanate 70
allopurinol 69
phenytoin 69
TMP/SMX Inj 68
cetirizine 67
amlodipine 65
SJS-TEN
lamotrigine 2639
valdecoxib 1402
ibuprofen 1048
allopurinol 887
phenytoin 791
carbamazepine 684
acetaminophen 653
ciprofloxacin 436
amoxicillin 347
levofloxacin 344
levetiracetam 339
TMP/SMX Inj 313
vancomycin 313
azithromycin 294
diclofenac 277
nevirapine 266
pembrolizumab 245
nivolumab 225
valproate 225
lenalidomide 216
ceftriaxone 213
furosemide 211
methotrexate 209
zonisamide 205
celecoxib 196
GBFDE
acetaminophen 27
metformin 15
ibuprofen 13
diclofenac 11
TMP/SMX Inj 8
tadalafil 6
amlodipine 5
ofloxacin 5
ceftriaxone 4
hydromorphone 4
naproxen 4
nicotine 4
carbamazepine 3
doxycycline 3
fluconazole 3
lansoprazole 3
DRESS
allopurinol 2269
lamotrigine 1894
vancomycin 1087
carbamazepine 914
amoxicillin 519
levetiracetam 507
phenytoin 441
ciprofloxacin 426
rifampin 412
TMP/SMX Inj 348
levofloxacin 345
sulfasalazine 337
minocycline 324
telaprevir 275
ceftriaxone 272
valproate 264
ibuprofen 249
pantoprazole 242
dapsone 223
zonisamide 206
atorvastatin 198
valacyclovir 198
isoniazid 194
esomeprazole 189
diclofenac 174
0
5
10


SJS-TEN/DRESS Co-reporting
Information Component (with 95% CI)
8
4
0
71
71
49
20
20
15
14
14
13
10
9
9
9
7
7
7
6
6
6
5
allopurinol
lamotrigine
phenytoin
carbamazepine
vancomycin
levetiracetam
ciprofloxacin
doxycycline
escitalopram
acetaminophen
ceftriaxone
rifampin
zonisamide
hydroxychloroquine
pantoprazole
valproate
amoxicillin
ibuprofen
sulfasalazine
meropenem
DRESS/AGEP Co-reporting
26
18
14
8
6
5
5
5
5
5
4
4
4
4
4
3
3
3
3
3
phenytoin
ciprofloxacin
allopurinol
carbamazepine
acetaminophen
hydroxychloroquine
ibuprofen
levofloxacin
tramadol
vancomycin
amoxicillin
azithromycin
cetirizine
methotrexate
valacyclovir
enoxaparin
esomeprazole
lamotrigine
moxifloxacin
terbinafine
SJS-TEN/AGEP Co-reporting
34
29
13
12
12
9
9
6
6
5
4
4
4
3
3
3
3
3
phenytoin
amlodipine
ibuprofen
acetaminophen
hydroxychloroquine
lamotrigine
metronidazole
amoxicillin
carbamazepine
terbinafine
ceftriaxone
cephalexin
levofloxacin
azithromycin
cetirizine
ciprofloxacin
clindamycin
diltiazem
Co-reporting Between SCAR
GBFDE
AGEP
DRESS
SJSTEN
4
0
2
150
231
205
6183
2
576
22444
205
0
28871
576
231
4
SJSTEN
DRESS
AGEP
GBFDE
600
500
400
300
200
100
0


AGEP
DRESS
GBFDE
SJS-TEN
p < 0.0001
1.00
0.75
0.50
0.25
0.00
0
10
20
30
40
50
60
70
80
Number at risk
AGEP 1541 367 88 0 0 0 0 0 0
DRESS 5021 3719 2520 1443 690 340 126 9 0
GBFDE 5 0 0 0 0 0 0 0 0
SJS-TEN 7230 4293 2227 1149 520 180 0 0 0
Days
SJS-TEN
zonisamide
vancomycin
valdecoxib
trimethoprim
TMP / SMX Inj
sulfasalazine
sorafenib
sertraline
phenytoin
pembrolizumab
pantoprazole
oxcarbazepine
omeprazole
nivolumab
nevirapine
levofloxacin
levetiracetam
lenalidomide
lansoprazole
lamotrigine
ibuprofen
furosemide
fluconazole
esomeprazole
enoxaparin
enfortumab
diclofenac
clindamycin
clavulanate
clarithromycin
ciprofloxacin
ceftriaxone
carboplatin
carbamazepine
azithromycin
aspirin
amoxicillin
amlodipine
allopurinol
acetaminophen
All Drugs
Causative Drug
0 10 20 30
DRESS
zonisamide
vemurafenib
vancomycin
valproate
valacyclovir
telaprevir
sulfasalazine
rifampin
raltegravir
pyrazinamide
pregabalin
pip / tazo Inj
phenytoin
pantoprazole
omeprazole
moxifloxacin
metronidazole
meropenem
linezolid
levofloxacin
levetiracetam
lenalidomide
lansoprazole
lamotrigine
ibuprofen
furosemide
fluconazole
esomeprazole
enoxaparin
cobimetinib
clindamycin
ciprofloxacin
ceftriaxone
cefotaxime
caspofungin
carbamazepine
atorvastatin
amoxicillin
amlodipine
allopurinol
acyclovir
acetaminophen
All Drugs
10 20 30 40 50 60
AGEP
vancomycin
valacyclovir
tramadol
terbinafine
ramipril
pantoprazole
ondansetron
omeprazole
metronidazole
metformin
meropenem
linezolid
levofloxacin
levetiracetam
lenalidomide
lansoprazole
imipenem
ibuprofen
hydroxyzine
hydroxychloroquine
furosemide
fluconazole
esomeprazole
enoxaparin
doxycycline
diltiazem
clindamycin
clavulanate
clarithromycin
ciprofloxacin
cefuroxime
ceftriaxone
cefotaxime
bisoprolol
azithromycin
atorvastatin
amoxicillin
amlodipine
allopurinol
acyclovir
acetaminophen
All Drugs
10
Median Latency, 25-75th %ile (Days)


FAERS Quarterly Files
(Jan. 2004 – Dec. 2023)
Reaction (REAC):
68,079,535 rows
Drug (DRUG):
81,643,965 rows
Outcome (OUTC):
68,078,521 rows
Demographics (DEMO):
20,836,820 rows
Therapeutics (THER):
30,810,202 rows
Deduplication and
Mapping (SQL)
Unique PIDs: 20,750,362
Mapped Adverse Events (REAC)
51,135,682 rows
Unique PIDs: 17,201,516
Mapped Drug (DRUG)
56,389,500 rows
Unique PIDs: 16,551,079
Unmapped Drug (DRUG):
808,310 rows (1.4%)
Unmapped Adverse Events (REAC):
598 rows (<0.01%)
Manual Mapping
Sanitized Drug Data
Sanitized Outcome Data
Unique PIDs: 17,201,564
Demographic Analysis
Disproportionality Analysis
Overlap Analysis
(SCAR cases: 56,683)
Mortality Analysis
(SCAR cases: 13,540)
Mortality Assignment
Sanitization
TTE Calculation,
Filtering
Latency/TTE Analysis
(SCAR Cases: 13,633)


All SCAR
Number of Patients
400
300
200
100
0
0
25
50
75
100
Age (Years)
SJS-TEN
200
150
100
50
0
DRESS
AGEP
60
40
20
GBFDE
2.0
1.5
1.0
0.5
0.0
Sex
Female
Male

Total SCAR



SJS-TEN



DRESS



AGEP



GBFDE




Information Component (with 95% CI)
-5
0
5
SCAR
lamotrigine 4508
allopurinol 3140
carbamazepine 1617
vancomycin 1584
ibuprofen 1504
valdecoxib 1406
phenytoin 1211
amoxicillin 1073
ciprofloxacin 961
levetiracetam 935
acetaminophen 910
levofloxacin 761
TMP / SMX Inj 730
ceftriaxone 604
valproate 508
clindamycin 495
diclofenac 490
rifampin 487
azithromycin 473
pantoprazole 467
sulfasalazine 445
zonisamide 402
omeprazole 387
metronidazole 386
furosemide 380
telaprevir 378
valacyclovir 365
esomeprazole 363
minocycline 352
amlodipine 333
hydroxychloroquine 332
lenalidomide 330
acyclovir 309
atorvastatin 309
doxycycline 301
nevirapine 297
nivolumab 292
terbinafine 289
lansoprazole 285
clarithromycin 270
pembrolizumab 268
methotrexate 267
trimethoprim 262
naproxen 253
celecoxib 252
pip / tazo Inj 252
fluconazole 251
dapsone 247
moxifloxacin 241
isoniazid 234
enoxaparin 226
clavulanate 200
pregabalin 199
aspirin 198
oxcarbazepine 196
linezolid 194
prednisolone 193
meropenem 188
metformin 185
cefuroxime 183
olanzapine 181
gabapentin 178
quetiapine 172
cephalexin 167
azathioprine 166
bupropion 165
cefotaxime 165
diltiazem 165
vemurafenib 162
adalimumab 159
rituximab 156
sertraline 152
dexamethasone 150
ranitidine 150
duloxetine 149
tramadol 146
aripiprazole 137
carboplatin 135
methylprednisolone 133
cetirizine 129
lamivudine 129
rosuvastatin 128
daptomycin 126
risperidone 122
ribavirin 121
bendamustine 117
phenobarbital 117
leflunomide 116
temozolomide 114
ondansetron 112
clopidogrel 111
abacavir 110
enfortumab 110
mirtazapine 110
ramipril 110
cefepime 109
sitagliptin 108
infliximab 105
oseltamivir 102
gemcitabine 99


SJS-TEN - Most Negative IC
DRESS - Most Negative IC
AGEP - Most Negative IC
Information Component (with 95% CI)
0.0
-2.5
-5.0
-7.5
levonorgestrel
rosiglitazone
fingolimod
ruxolitinib
evolocumab
natalizumab
denosumab
somatropin
dupilumab
oxycodone
tofacitinib
vedolizumab
liraglutide
buprenorphine
palbociclib
tiotropium
testosterone
cinacalcet
abatacept
apremilast
etanercept
tofacitinib
dupilumab
adalimumab
apremilast
natalizumab
abatacept
insulin glargine
oxycodone
zoledronic acid
varenicline
vedolizumab
denosumab
albuterol
ocrelizumab
infliximab
mycophenolate mofetil
eculizumab
methylphenidate
dimethyl fumarate
etanercept
secukinumab
apremilast
adalimumab
dupilumab
valsartan
ustekinumab
ranitidine
bevacizumab
oxycodone
palbociclib
tacrolimus
denosumab
lenalidomide
pregabalin
apixaban
budesonide
tocilizumab
zoledronic acid
aripiprazole

Co-reporting Between Cutaneous ADR